895 related articles for article (PubMed ID: 18221256)
1. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
[TBL] [Abstract][Full Text] [Related]
2. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
[TBL] [Abstract][Full Text] [Related]
3. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
4. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
5. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis.
Cheung CY; Chan HW; Liu YL; Chau KF; Li CS
Nephrology (Carlton); 2009 Dec; 14(8):758-63. PubMed ID: 20025685
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
[TBL] [Abstract][Full Text] [Related]
7. Pediatric liver transplantation with daclizumab induction.
Heffron TG; Pillen T; Smallwood GA; Welch D; Oakley B; Romero R
Transplantation; 2003 Jun; 75(12):2040-3. PubMed ID: 12829908
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
10. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
Ji SM; Li LS; Cheng Z; Cheng DR; Sun QQ; Chen JS; Sha GZ; Liu ZH
Transplant Proc; 2007 Jun; 39(5):1396-401. PubMed ID: 17580147
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
Kobashigawa J; David K; Morris J; Chu AH; Steffen BJ; Gotz VP; Gordon RD
Transplant Proc; 2005 Mar; 37(2):1333-9. PubMed ID: 15848713
[TBL] [Abstract][Full Text] [Related]
12. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
[TBL] [Abstract][Full Text] [Related]
13. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
15. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
[TBL] [Abstract][Full Text] [Related]
16. European randomised trial of dual versus triple tacrolimus-based regimens for control of acute rejection in renal allograft recipients.
Chang RW; Snowden S; Palmer A; Kwan JT; Nicholson M; Kashi SH; Fernando ON; Perner F; Neild GH
Transpl Int; 2001 Dec; 14(6):384-90. PubMed ID: 11793035
[TBL] [Abstract][Full Text] [Related]
17. Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients.
Cheung CY; Wong KM; Chan HW; Liu YL; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Li CS
Transpl Int; 2006 Aug; 19(8):657-66. PubMed ID: 16827683
[TBL] [Abstract][Full Text] [Related]
18. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
[TBL] [Abstract][Full Text] [Related]
19. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
20. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]